David Amsellem
Stock Analyst at Piper Sandler
(4.32)
# 685
Out of 4,479 analysts
93
Total ratings
52.94%
Success rate
15.54%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Reiterates: Overweight | $35 | $31.56 | +10.90% | 3 | Jul 1, 2024 | |
| AMPH Amphastar Pharmaceuticals | Reiterates: Overweight | $71 | $37.58 | +88.93% | 4 | Jun 27, 2024 | |
| TEVA Teva Pharmaceutical | Reiterates: Overweight | $19 → $20 | $16.55 | +20.85% | 6 | May 13, 2024 | |
| XERS Xeris Biopharma Holdings | Reiterates: Overweight | $4 → $3 | $2.06 | +45.63% | 3 | May 10, 2024 | |
| RVNC Revance Therapeutics | Reiterates: Overweight | $20 → $11 | $2.42 | +354.55% | 6 | May 10, 2024 | |
| COLL Collegium Pharmaceutical | Downgrades: Neutral | $39 | $32.04 | +21.72% | 3 | May 10, 2024 | |
| OGN Organon & Co. | Maintains: Overweight | $22 → $24 | $20.12 | +19.28% | 5 | Apr 29, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Overweight | $10 | $2.42 | +313.22% | 1 | Apr 11, 2024 | |
| ALKS Alkermes | Reiterates: Overweight | $39 | $24.19 | +61.22% | 6 | Apr 1, 2024 | |
| VTRS Viatris | Reiterates: Neutral | $11 → $13 | $10.43 | +24.64% | 5 | Mar 28, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $6 → $8 | $6.54 | +22.32% | 3 | Mar 21, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $171 → $188 | $105.09 | +78.89% | 4 | Mar 20, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Overweight | $18 → $23 | $13.89 | +65.59% | 3 | Mar 5, 2024 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $45 → $41 | $25.77 | +59.10% | 9 | Feb 28, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $20 → $21 | $6.22 | +237.62% | 3 | Feb 16, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $90 → $113 | $78.93 | +43.16% | 3 | Jan 16, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $33 → $45 | $41.23 | +9.14% | 2 | Dec 7, 2023 | |
| CARA Cara Therapeutics | Downgrades: Neutral | $12 → $1 | $0.28 | +259.84% | 3 | Nov 14, 2023 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $50 → $42 | $22.74 | +84.70% | 6 | Nov 3, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $95 → $100 | $137.49 | -27.27% | 4 | Nov 1, 2023 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $72 → $42 | $30.00 | +40.00% | 3 | Oct 16, 2023 | |
| OPTN OptiNose | Maintains: Overweight | $4 → $3 | $1.04 | +188.46% | 1 | Aug 11, 2023 | |
| EGRX Eagle Pharmaceuticals | Downgrades: Underweight | $26 → $17 | $5.23 | +225.05% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Maintains: Neutral | $7 → $6 | $7.11 | -15.61% | 3 | Sep 9, 2022 | |
| EVFM Evofem Biosciences | Maintains: Overweight | $3,750 → $250 | $0.01 | +2,272,627.27% | 2 | May 25, 2022 |
Corcept Therapeutics
Jul 1, 2024
Reiterates: Overweight
Price Target: $35
Current: $31.56
Upside: +10.90%
Amphastar Pharmaceuticals
Jun 27, 2024
Reiterates: Overweight
Price Target: $71
Current: $37.58
Upside: +88.93%
Teva Pharmaceutical
May 13, 2024
Reiterates: Overweight
Price Target: $19 → $20
Current: $16.55
Upside: +20.85%
Xeris Biopharma Holdings
May 10, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $2.06
Upside: +45.63%
Revance Therapeutics
May 10, 2024
Reiterates: Overweight
Price Target: $20 → $11
Current: $2.42
Upside: +354.55%
Collegium Pharmaceutical
May 10, 2024
Downgrades: Neutral
Price Target: $39
Current: $32.04
Upside: +21.72%
Organon & Co.
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $20.12
Upside: +19.28%
Aquestive Therapeutics
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $2.42
Upside: +313.22%
Alkermes
Apr 1, 2024
Reiterates: Overweight
Price Target: $39
Current: $24.19
Upside: +61.22%
Viatris
Mar 28, 2024
Reiterates: Neutral
Price Target: $11 → $13
Current: $10.43
Upside: +24.64%
Amneal Pharmaceuticals
Mar 21, 2024
Maintains: Overweight
Price Target: $6 → $8
Current: $6.54
Upside: +22.32%
Jazz Pharmaceuticals
Mar 20, 2024
Reiterates: Overweight
Price Target: $171 → $188
Current: $105.09
Upside: +78.89%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Overweight
Price Target: $18 → $23
Current: $13.89
Upside: +65.59%
Supernus Pharmaceuticals
Feb 28, 2024
Maintains: Overweight
Price Target: $45 → $41
Current: $25.77
Upside: +59.10%
Ironwood Pharmaceuticals
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $6.22
Upside: +237.62%
Axsome Therapeutics
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $78.93
Upside: +43.16%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $33 → $45
Current: $41.23
Upside: +9.14%
Cara Therapeutics
Nov 14, 2023
Downgrades: Neutral
Price Target: $12 → $1
Current: $0.28
Upside: +259.84%
Pacira BioSciences
Nov 3, 2023
Maintains: Overweight
Price Target: $50 → $42
Current: $22.74
Upside: +84.70%
Neurocrine Biosciences
Nov 1, 2023
Maintains: Neutral
Price Target: $95 → $100
Current: $137.49
Upside: -27.27%
Harmony Biosciences Holdings
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $30.00
Upside: +40.00%
OptiNose
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $3
Current: $1.04
Upside: +188.46%
Eagle Pharmaceuticals
Aug 9, 2023
Downgrades: Underweight
Price Target: $26 → $17
Current: $5.23
Upside: +225.05%
Bausch Health Companies
Sep 9, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $7.11
Upside: -15.61%
Evofem Biosciences
May 25, 2022
Maintains: Overweight
Price Target: $3,750 → $250
Current: $0.01
Upside: +2,272,627.27%